• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Akebia Therapeutics (NQ: AKBA )

    1.690 +0.030 (+1.81%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Akebia Therapeutics

    < Previous 1 2 3 4 5 6 Next >
    See Why Does HC Wainwright Maintain Neutral On Akebia Stock
    Akebia Therapeutics Inc (NASDAQ: AKBA) announced three poster presentations at the National Kidney Foundation (NKF) Spring Clinical Meetings 2022.  
    Via Benzinga
    FDA Places Partial Hold On Vadadustat Pediatric Studies, Akebia Cuts Over 40% Staff
    Via Benzinga
    Stocks That Hit 52-Week Lows On Monday
    On Monday, 78 companies set new 52-week lows. Key Facts About Today's 52-Week Lows: Citigroup (NYSE:C) was the biggest company by market cap to set a new 52-week low.... 
    Via Benzinga
    FDA Rejects Akebia Therapeutics' Vadadustat For CKD-Associated Anemia
    Via Benzinga
    Earnings Scheduled For March 1, 2022
    Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated... 
    Via Benzinga
    The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight
    Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that... 
    Via Benzinga
    ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action AKBA
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates
    Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with... 
    Via Benzinga
    Stocks That Hit 52-Week Lows On Friday
    On Friday, 111 companies set new 52-week lows. Interesting Points From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was Citigroup (... 
    Via Benzinga
    53 Biggest Movers From Yesterday
    Gainers Longeveron Inc. (NASDAQ: LGVN) shares jumped 105.4% to close at $13.80 on Thursday after the company announced the publication of results from a Phase 1 trial testing... 
    Via Benzinga
    6 Stocks Halted In Wednesday's Session
    A circuit breaker is an automatic, temporary trading halt on certain securities when the underlying stock is experiencing times of high volatility. It is a measure put in place to... 
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Gainers Adagio Therapeutics (NASDAQ:ADGI) shares rose 40.0% to $5.39 during Wednesday's regular session. Trading volume for this security as of 13:31 EST is 80.0... 
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2022
    Upgrades 
    Via Benzinga
    NASDAQ:AKBA Investor Notice: Lawsuit Alleges Securities Laws Violations by Akebia Therapeutics, Inc.
    San Diego, CA -- (SBWIRE) -- 03/30/2022 -- An investor, who purchased shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA), filed a lawsuit over alleged violations of Federal Securities Laws by Akebia... 
    Via SBWire
    35 Stocks Moving In Wednesday's Mid-Day Session
    Gainers Direct Digital Holdings, Inc. (NASDAQ: DRCT) shares jumped 82.6% to $4.71 after the company reported a year over year increase in Q4 sales results and issued Q1 sales... 
    Via Benzinga
    51 Biggest Movers From Yesterday
    Gainers Forge Global Holdings, Inc. (NYSE: FRGE) jumped 73.9% to close at $37.64. Direct Digital Holdings, Inc. (NASDAQ: DRCT) shares surged 60.5% to close at $4.14 on Wednesday... 
    Via Benzinga
    The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
    Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets. 
    Via Benzinga
    Bronstein, Gewirtz & Grossman, LLC Notifies Akebia Therapeutics, Inc. (AKBA) Shareholders of Class Action and Encourages Investors to Contact the Firm
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    ROSEN, A LEADING LAW FIRM, Encourages Akebia Therapeutics, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – AKBA
    From The Rosen Law Firm, P.A.
    Via Business Wire
    AKEBIA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Akebia Therapeutics, Inc. and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire, P.C.
    Via Business Wire
    AKBA EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – AKBA
    From Rosen Law Firm
    Via Business Wire
    7 Biotech Stocks With Key Catalysts in March
    These seven stocks have some key catalysts lined up for March with the potential to move their price actions in big ways. 
    Via InvestorPlace
    Akebia Therapeutics Earnings Perspective: Return On Capital Employed
    Benzinga Pro data, Akebia Therapeutics (NASDAQ:AKBA) reported Q4 sales of $59.60 million. Earnings fell to a loss of $70.68 million, resulting in a 18.7% decrease from last... 
    Via Benzinga
    Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates
    The Food and Drug Administration approval calendar was light in February. Nevertheless, the month saw regulatory nods accorded to some breakthrough therapies. Agios... 
    Via Benzinga
    Recap: Akebia Therapeutics Q4 Earnings
    Akebia Therapeutics (NASDAQ:AKBA) reported its Q4 earnings results on Tuesday, March 1, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Earnings... 
    Via Benzinga
    7 Speculative Penny Stocks Worth a Roll of the Dice
    Under any circumstance, penny stocks are extremely risky. However, their under-the-radar profile could be intriguing right now. 
    Via InvestorPlace
    The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development
    Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase... 
    Via Benzinga
    Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Akebia Therapeutics, Inc. (AKBA) Investigation
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    Canadian Biotech Disruptor Lexston Life Sciences is unlocking the God Molecule (LEXTF, ICPT, AKBA, QURE, BNTX, SAVA)
    Via AB Newswire
    Topics Bonds Stocks
    Exposures Debt Markets US Equities
    < Previous 1 2 3 4 5 6 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.